Basic HTML Version
12
Choroby Serca i Naczyń 2012, tom 9, nr 1
www.chsin.viamedica.pl
33. Rathamann W., Frankhouser E., Dyer A.R., Roseman J.M. Relation of hyperuri-
cemia with the various components of the insulin resistance syndrome in young
black and white adults: the CARDIA study. Coronary Artery Risk Development
in Young Adults.
Ann. Epidemol.
1998; 8: 250–261.
34. Blumenthal D., Brunton L., Buxton I., Parker K. Diuretics. W: Blumenthal D., Brun-
ton L., Buxton I., Parker K. (red.). Goodman &Gilman’s manual of pharmacology
and therapeutics.McGraw-Hill Professional Publishing, NewYork 2008: 484–495.
35. Leary W.P., Reyes A.J., van der Byl K., Acosta-Barrios T.N. Effects of captopril,
hydrochlorothiazide and their combination on timed urinary excretion of water
and electrolytes.
J. Cardiovasc. Pharmacol.
1985; 7 (supl. 1): S56–S62.
36. Lant A.F., McNabb R.W., Noormohamed F.H. Kinetic andmetabolic aspects of
enalapril action.
J. Hypertens.
1984; 2
(supl.): S37–S42.
37. Reyes A.J., Leary W.P., van der Byl K., Santoni J.P. Effects of the angiotensin-I
converting enzyme inhibitor perindopril on timed urinary excretion of water and
solutes in healthy subjects.
Curr. Ther. Res. Clin. Exp.
1988; 44: 619–629.
38. MazzaliM.,HughesJ., KimY.G.i wsp. Elevateduricacid increasesbloodpressure in
theratbyanovelcrystal-independentmechanism.
Hypertension
2001;38:1101–1106.
39. Egan B.M., Weder A.B., Petrin J., Hoffman R.G. Neurohumoral and metabolic
effects of short-termdietary NaCl restriction inmen. Relationship to salt-sensiti-
vity status.
Am. J. Hypertens.
1991; 4: 416–421.
40. de la Sierra A., Lluch M.M., Coca A. i wsp. Fluid, ionic and hormonal changes
induced by high salt intake in salt-sensitive and salt-resistant hypertensive pa-
tients
. Clin. Sci.
(Lond.) 1996; 91: 155–161.
41. Desco M.C., Asensi M., Marquez R. i wsp. Xanthine oxidase is involved in free
radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002;
51: 1118–1124.
42. George J., Carr E., Davies J., Belch J.J., Struthers A. High-dose allopurinol im-
proves endothelial function by profoundly reducing vascular oxidative stress and
not by lowering uric acid.
Circulation
2006; 114: 2508–2516.
43. Cingolani H.E., Plastino J.A., Escudero E.M., Mangal B., Brown J., Perez N.G.
The effect of xanthine oxidase inhibition upon ejection fraction in heart failure pa-
tients: La Plata study.
J. Card. Fail.
2006; 12: 491–498.
44. Hare J.M., Mangal B., Brown J. i wsp. Impact of oxypurinol in patients with symp-
tomatic heart failure. Results of the OPT-CHF study.
J. Am. Coll. Cardiol.
2008;
51: 2301–2309.
45. Bergamini C., Cicoira M., Rossi A., Vassanelli C. Oxidative stress and hyperuri-
caemia: pathophysiology, clinical relevance, and therapeutic implications inchro-
nic heart failure.
Eur. J. Heart Fail.
2009; 11: 444–452.
46. George J., Struthers A. The OPT-CHF (Oxypurinol Therapy for Congestive
Heart Failure) trial: a question of dose.
J. Am. Coll. Cardiol.
2009; 53: 2405.